Skip to content

Study · Randomized controlled trial · n = 792 · 2025

7 results

Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.

Rasouli N, Guder Arslan E, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Sourij H, Thomas S, Verma S, Bonaca MP

Diabetes care1 Sept 2025Cited by 9 (Europe PMC)

PMID40543068 (opens in a new tab)PMCIDPMC12368379 (opens in a new tab)DOI10.2337/dc25-1082 (opens in a new tab)PepBankPUB-40543068
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with symptomatic peripheral artery disease and type 2 diabetes, semaglutide improved pain-free walking distance across subgroups, with no treatment-by-subgroup interaction (P > 0.1).

    In plain wordsIn people with leg artery disease and type 2 diabetes, semaglutide improved pain-free walking distance in all subgroups.

    Peptide
    Semaglutide
    Outcome
    IncreasePain-free walking distance across subgroups
    Study

    n = 792

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide also improved PFWD across subgroups (P > 0.1 for all interactions).
    2 context sentences
    Summary · context
    The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic…
    Summary · context
    Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with symptomatic peripheral artery disease and type 2 diabetes, semaglutide improved maximum walking distance regardless of diabetes duration (ratio to baseline 1.15 for under 10 years vs 1.13 for 10 years or more).

    In plain wordsIn people with leg artery disease and type 2 diabetes, semaglutide improved walking distance whether diabetes was shorter or longer than 10 years.

    Peptide
    Semaglutide
    Outcome
    IncreaseMaximum walking distance by diabetes duration
    Study

    n = 792

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Ratio to baseline in MWD
    1.15 ratio
    diabetes duration <10 years
    Ratio to baseline in MWD
    1.13 ratio
    diabetes duration >=10 years

    Source sentences

    Summary
    Semaglutide significantly improved MWD regardless of diabetes duration (ETR of 1.15 vs. 1.13 for <10 vs. ≥10 years, P = 0.80)
    2 context sentences
    Summary · context
    The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic…
    Summary · context
    Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with symptomatic peripheral artery disease and type 2 diabetes, semaglutide improved maximum walking distance regardless of BMI (ratio to baseline 1.12 for BMI under 30 vs 1.16 for 30 or more).

    In plain wordsIn people with leg artery disease and type 2 diabetes, semaglutide improved walking distance whether BMI was below or above 30.

    Peptide
    Semaglutide
    Outcome
    IncreaseMaximum walking distance by BMI
    Study

    n = 792

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Ratio to baseline in MWD
    1.12 ratio
    BMI <30
    Ratio to baseline in MWD
    1.16 ratio
    BMI >=30

    Source sentences

    Summary
    BMI (1.12 vs. 1.16 for <30 vs. ≥30 kg/m2, P = 0.58)
    2 context sentences
    Summary · context
    The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic…
    Summary · context
    Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with symptomatic peripheral artery disease and type 2 diabetes, semaglutide improved maximum walking distance regardless of HbA1c (ratio to baseline 1.13 for both under 7% and 7% or more).

    In plain wordsIn people with leg artery disease and type 2 diabetes, semaglutide improved walking distance at lower and higher HbA1c levels alike.

    Peptide
    Semaglutide
    Outcome
    IncreaseMaximum walking distance by HbA1c
    Study

    n = 792

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Ratio to baseline in MWD
    1.13 ratio
    HbA1c <7% and >=7%

    Source sentences

    Summary
    HbA1c (1.13 for <7% and ≥7%, P = 0.99)
    2 context sentences
    Summary · context
    The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic…
    Summary · context
    Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In people with symptomatic peripheral artery disease and type 2 diabetes, semaglutide improved maximum walking distance regardless of diabetes medication use.

    In plain wordsIn people with leg artery disease and type 2 diabetes, semaglutide improved walking distance whatever diabetes medicines they used.

    Peptide
    Semaglutide
    Outcome
    IncreaseMaximum walking distance by diabetes medication use
    Study

    n = 792

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    or medication use.
    2 context sentences
    Summary · context
    The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic…
    Summary · context
    Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin.
  6. 06HumanRandomized controlled trialMechanism

    In people with symptomatic peripheral artery disease and type 2 diabetes, BMI reduction correlated only weakly with improvements in maximum walking distance.

    In plain wordsIn people with leg artery disease and type 2 diabetes, weight loss was only weakly linked to walking gains.

    Peptide
    Semaglutide
    Outcome
    Not applicableBMI reduction and maximum walking distance improvement
    Study

    n = 792

    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    BMI reduction correlated weakly with MWD improvements
    2 context sentences
    Summary · context
    The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic…
    Summary · context
    Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin.
  7. 07HumanRandomized controlled trialSafety outcome

    In people with symptomatic peripheral artery disease and type 2 diabetes, safety outcomes with semaglutide were consistent across subgroups.

    In plain wordsIn people with leg artery disease and type 2 diabetes, side effects were similar across the subgroups studied.

    Peptide
    Semaglutide
    Outcome
    No significant changeSafety outcomes across subgroups
    Study

    n = 792

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.0 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Safety outcomes were consistent across subgroups.
    2 context sentences
    Summary · context
    The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic…
    Summary · context
    Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.